Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4, indicating a backend/template update to the page without changing the displayed study information.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe study record was updated to add Janssen Scientific Affairs, LLC as a collaborator and remove the National Cancer Institute (NCI); recent timestamps indicate that the record has been refreshed.SummaryDifference0.3%

- Check35 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check56 days agoChange DetectedAdded 'Multiple myeloma' as a topic and included a new Resources link to Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check71 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.1%

Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.